Ambroxol as a Disease-modifying Treatment in GBA-PD

Study Overview
=================
Brief Summary
-----------------
The present multicenter, randomized, double-blind, placebo-controlled clinical trial will investigate whether the prolonged administration of high-dose oral Ambroxol over 52 weeks is safe, tolerable, able to change Glucocerebrosidase enzyme activity and alpha-synuclein levels in the central nervous system and, ultimately, to reduce the progression of cognitive decline and motor disability in 60 individuals with Parkinson's disease with mutations of the glucocerebrosidase gene (GBA1; OMIM 606463). Participants will undergo clinical, biomarker blood and cerebrospinal fluid analysis, neuropsychological, neuroimaging assessment throughout the course of the study.

Detailed Description
-----------------
Glucocerebrosidase (GCase) is a lysosomal enzyme encoded by the GBA1 beta-glucosylceramidase gene (GBA). Heterozygous GBA mutations are recognized as the most frequent genetic risk factor for Parkinson's disease (PD),with an overall carrier frequency of about 10% in PD. Heterozygous carriers of GBA mutations are at increased odds for developing PD and even higher for PD Dementia and Dementia with Lewy Bodies. In GBA carriers, PD usually occurs at earlier age at onset, higher risk for dementia, visual hallucinations, autonomic dysfunction and faster progression of motor symptoms than noncarriers, culminating in an overall reduced survival. GBA1 mutations reduce the enzymatic function of GCase, ultimately promoting the toxic accumulation of alpha-synuclein (alpha-syn) fibrils throughout the central nervous system. The toxic conversion of physiological alpha-syn conformers by glycosphingolipids should be reversible at a stage prior to incorporation into fibrils. Therefore, the use of agents able to enhance GCase activity might hold a therapeutic potential. Ambroxol is a metabolite of bromhexine which has been used for over 30 years as an over-the-counter mucolytic, with an excellent safety profile with few side effects. The brain penetrance of Ambroxol in vivo and its ability to increase GCase activity and reduce alpha-syn levels has been consistently confirmed in several in vitro and in vivo studies, but only at a higher dose (1.2 g/day in humans). The investigators hypothesize that the greatest impact of Ambroxol as a disease-modifying agent will be on cognitive performance, because it is the clinical feature that showed the greatest difference between PD carriers vs. non-carriers. Sixty patients diagnosed with PD and carriers of GBA mutations will be recruited and randomly allocated to either Ambroxol 1.2 g/day or Placebo. Galenic formulation of Ambroxol 200 mg per tablet and similar Placebo tablets have been manufactured ad hoc and their use in this study has been authorized by the Italian Medicines Agency (AIFA; Provvedimento 2021-004565-13 SC23119). The investigators will administer clinical and cognitive assessments to determine if there is any difference in the progression of cognitive dysfunction (primary endpoint) as well as other motor and non-motor features between the two treatment arms. Pharmacokinetics (Ambroxol drug levels) and pharmacodynamics (GCase enzyme activity) of the experimental drug in blood and cerebrospinal fluid samples will be measured as well as neurodegeneration biomarkers in the cerebrospinal fluid (alpha-synuclein, Tau, phospho-Tau and beta amyloid-42) at baseline and after the intake of oral Ambroxol for 12 months.

Official Title
-----------------
Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

Conditions
-----------------
Parkinson Disease, GBA Gene Mutation

Intervention / Treatment
-----------------
* Drug: Ambroxol Hydrochloride
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 21-80 years Diagnosis of idiopathic PD Duration of motor symptoms >5 years Heterozygous carrier of a GBA1 mutation. Capable of complying with all study procedures, including fasting lumbar puncture All male and female participants of childbearing age must agree with their partners to use double barrier birth control or total abstinence during study participation and for 2 weeks after the last dose of study drug. Male participants who have received bilateral vasectomy are permanently sterile. A woman can participate if she is of: Non-childbearing potential Women of childbearing potential must have a negative pregnancy test at the screening visit and use accepted contraceptive methods defined as highly effective. Exclusion Criteria: Secondary and primary atypical parkinsonism Diagnosis of Parkinson-Dementia (MDS Level II criteria) or other conditions that result in inability to understand and sign the informed consent Hoehn & Yahr stage ≥ 4/5 in the medication-ON condition Deep Brain Stimulation Any clinically significant or unstable medical condition, which, in the opinion of the principal investigator or the clinician delegated by the principal investigator, may put the participant at risk when participating in the study (e.g. previous gastric/duodenal peptic ulcer, chronic obstructive pulmonary disease, severe liver or kidney changes, major cardiovascular event (e.g. myocardial infarction, decompensated congestive heart failure, pulmonary embolism occurring within 6 months prior to the screening visit), neoplastic diseases). Bronchial asthma Abnormalities that could preclude safe completion of the spinal cord in the investigator's opinion, including: treatment with anticoagulants; severe abnormalities or malformations of the lower spine or other spinal disorders; bleeding diathesis (e.g. clinically significant coagulopathies or thrombocytopenia); hypersensitivity to lidocaine. Pregnant or breastfeeding women. All participants of childbearing age who disagree to use double barrier or abstinence birth control while participating in the study and for 2 weeks after the last dose of study drug; Known hypersensitivity to the active substance Ambroxol or to any of its excipients.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group trial
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ambroxol<br>Ambroxol hydrochloride 200 mg tablets Dose: 1.2 g daily Escalation scheme: Day 1 - 5 200 mg 200 mg once a day Day 6 - 10 400 mg 200 mg twice a day Day 11 - 15 600 mg 200 mg three times a day Day 16 - 20 800 mg 400 mg twice a day Day 21 - 25 1000 mg 400 mg + 200 mg + 400 mg a day Day 26 - 365 1200 mg 400 mg three times a day | Drug: Ambroxol Hydrochloride<br>* Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.<br>* Other names: Ambroxol;|
| Placebo Comparator: Placebo<br>Excipients | Drug: Placebo<br>* Excipients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in Montreal Cognitive Assessment score | This 30-point test investigates global cognitive functions and it has been recommended for the assessment of Parkinson's dementia. The lower the score the worse the cognitive functions. | baseline and week 52 | 
| Change from baseline in conversion rate from normal cognitive function (PD-N) to mild cognitive impairment (PD-MCI) and from PD-N or PD-MCI to Parkinson-Dementia (PD-D) | Rate of conversion from normal cognitive status to MCI or from MCI to overt dementia over the 52-week treatment period | baseline and week 52 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of treatment-related adverse events and drop-outs | Assessment of any treatment-related adverse events and drop-outs throughout the whole study period | Day 1-372 | 
| Change from baseline in Parkinson Disease Cognitive Functional Rating Scale (PD-CFRS) | The PD-CFRS is a short questionnaire addressed to explore a wide range of functional aspects sensible to detect cognitive impairment in PD, minimizing the motor impact of the disease. The scale is administered to a knowledgeable informant in interview form by 12 items selected to cover the spectrum of instrumental cognitive changes seen in PD over the last two weeks before the evaluation (exploring for example whether or not the patient has had trouble in handling money, domestic economy, controlling drug treatment schedule, organizing daily activities, handling home electrical appliances, understanding how to use public transport, solving unforeseen events, explaining things he/she want to say, and handling the cell phone). The score ranges from 0 to 24; the higher the score the worse the disability. | baseline and week 52 | 
| Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II | MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions completed by the participant. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. | baseline, week 26 and week 52 | 
| Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III | Changes on a validated scale used to assess motor performance. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part III assesses the motor signs of PD and is administered by the rater (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. | baseline, week 26 and week 52 | 
| Change from baseline in Hoehn and Yahr stage | This is a 5-points staging of Parkinson's disease. The higher the stage the worse the motor disability | baseline, week 26 and week 52 | 
| Change from baseline in glucocerebrosidase enzyme activity in blood leucocytes and cerebrospinal fluid | Pharmacodynamic effects of Ambroxol will be measured through the change from baseline in glucocerebrosidase enzyme activity in blood leucocytes (nmol/mg/h) and cerebrospinal fluid (nmol/mL/h), using the substrate 4-methylumbelliferyl-β-D-glucopyranoside. This outcome measure aims to investigate whether ambroxol oral administration is able to target the glucocerebrosidase pathway in PD and increase GCase enzyme activity in peripheral blood mononuclear cells and in the central nervous system. | baseline and week 52 | 
| Penetration of Ambroxol into the cerebrospinal fluid | Assess ambroxol cerebrospinal fluid penetration by measuring the ratio (expressed in %) between Ambroxol levels in blood serum (ng/mL) and in the cerebrospinal fluid (ng/ml) | week 26 and week 52 | 
| Changes in Cerebrospinal Fluid biomarkers of neurodegeneration | Quantify the effects of Ambroxol on biomarkers of neurodegeneration | baseline and week 52 | 
| Changes in functional connectivity at rest using brain magnetic resonance imaging | Imaging biomarker of neurodegeneration | baseline and week 52 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson disease, glucocerebrosidase, GBA, ambroxol, placebo, disease-modifying, randomized clinical trial